文献速递临床微生物质量管理与危急值

两种直接药敏试验对肠杆菌目血流感染疗效的准确性比较

Accuracy of Two Direct Antibiotic-Susceptibility Tests and Their Impact on the Optimal Treatment of Enterobacterales-Associated Bloodstream Infection: Comparison of the QMAC-dRAST V2.5 and BD Phoenix M50 Systems.
PubMed 文献 · Ann Lab Med · 2025-10-13

该研究回顾性分析106株肠杆菌目血流感染分离株,比较QMAC-dRAST与BD Phoenix M50直接药敏试验与常规肉汤微量稀释法的一致性及对治疗调整的影响。两种系统总体分类一致率均约93%,但哌拉西林-他唑巴坦的极重大误差较高;直接药敏试验平均报告时间更短,且 optimal 治疗比例从46.7%升至78.3%。

要点

  • QMAC-dRAST与dPhoenix总体分类一致率分别为93.6%和93.1%,可接受。
  • 哌拉西林-他唑巴坦极重大误差高(QMAC-dRAST 20.0%,dPhoenix 15.0%),需补充试验。
  • 直接药敏试验平均报告时间短于常规方法,并提高 optimal 治疗比例。

核心结论

  • QMAC-dRAST和dPhoenix直接药敏试验结果可靠且报告时间短,但哌拉西林-他唑巴坦需补充试验如纸片扩散法。

研究设计与样本

  • 回顾性分析106株肠杆菌目血流感染分离株,比较两种直接药敏试验与常规肉汤微量稀释法,并评估治疗调整。

主要发现

  • QMAC-dRAST总体分类一致率93.6%、极重大误差1.6%、重大误差0.9%、次要误差5.3%。
  • dPhoenix总体分类一致率93.1%、极重大误差0.9%、重大误差0.6%、次要误差6.2%。
  • 哌拉西林-他唑巴坦极重大误差:QMAC-dRAST 4/20(20.0%),dPhoenix 3/20(15.0%)。
  • 平均报告时间:QMAC-dRAST 20.8小时,dPhoenix 30.1小时(P <0.001)。
  • 直接药敏试验后 optimal 治疗从43例(46.7%)增至72例(78.3%)(P <0.001)。

关键数值与推荐

  • QMAC-dRAST总体分类一致率93.6%,极重大误差1.6%,重大误差0.9%,次要误差5.3%。
  • dPhoenix总体分类一致率93.1%,极重大误差0.9%,重大误差0.6%,次要误差6.2%。
  • 哌拉西林-他唑巴坦极重大误差:QMAC-dRAST 20.0%,dPhoenix 15.0%。
  • 平均报告时间:QMAC-dRAST 20.8小时,dPhoenix 30.1小时(P <0.001)。
  • optimal 治疗比例从46.7%增至78.3%(P <0.001)。

临床怎么用

  • 两种直接药敏试验可用于肠杆菌目血流感染快速药敏,但哌拉西林-他唑巴坦结果需纸片扩散法等补充试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid pathogen identification and antibiotic-susceptibility tests (ASTs) are important for treating bloodstream infections. We compared the performance of the QMAC-dRAST and BD Phoenix M50 direct AST (dPhoenix) systems using bacterial pellets prepared from positive blood culture broth and evaluated their impact on treatment modification. METHODS: Direct AST results for 106 Enterobacterales isolates were retrospectively reviewed. Conventional broth microdilution was used to calculate categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE). For isolates showing high VMEs in both methods, supplementary tests were performed. Clinical impact was evaluated by calculating the time required to obtain AST results (time-to-result) and observing changes in antibiotics prescribed after performing ASTs. RESULTS: Both systems showed acceptable overall CA, VME, ME, and mE values (QMAC-dRAST: 93.6%, 1.6%, 0.9%, and 5.3%, respectively; dPhoenix: 93.1%, 0.9%, 0.6%, and 6.2%, respectively). Piperacillin-tazobactam showed high VMEs with QMAC-dRAST (4/20, 20.0%) and dPhoenix (3/20, 15.0%). Colony AST on 13 isolates revealed that QMAC-dRAST testing yielded lower minimal inhibitory concentrations (MICs) for piperacillin-tazobactam with three isolates, whereas dPhoenix testing yielded higher MICs with two isolates and lower MICs with two isolates. The average time-to-result was 20.8 hr and 30.1 hr for QMAC-dRAST and dPhoenix, respectively (P <0.001). After AST, the number of optimal treatments increased from 43 (46.7%) to 72 (78.3%) (P <0.001). CONCLUSIONS: The QMAC-dRAST and dPhoenix systems provided reliable AST results with a short time-to-result. However, we recommend performing complementary tests, such as the disk diffusion test, for piperacillin-tazobactam.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Yoon JS, Kwon JA, Shin JS, et al. Accuracy of Two Direct Antibiotic-Susceptibility Tests and Their Impact on the Optimal Treatment of Enterobacterales-Associated Bloodstream Infection: Comparison of the QMAC-dRAST V2.5 and BD Phoenix M50 Systems. Ann Lab Med. 2025. PMID: 41077960. doi:10.3343/alm.2025.0246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。